Bastide Le Confort shares down 16.9% over the quarter despite higher Q1 revenue
The home healthcare provider is moving against the trend of a downward Paris session. The stock remains close to break-even while the CAC 40 falls sharply, amid a global correction in technology stocks.
Bastide Le Confort shares fell 0.52% to €19.08 intraday, while the SBF 120 dropped 1.39% and the CAC 40 fell 1.34%. The stock thus remains slightly above its 20-day moving average (€18.94, a gap of 0.74%), while the 50-day moving average (€19.34) is still within reach.
Over the week, the stock lost 4.51%, but this decline was accompanied by a publication of revenue up 7.5% in the first quarter, released on November 12. The group generated €124.3 million in its first quarter ended September 30, representing 7.1% organic growth, and maintains its target of €500 million.
Growth driven by international markets and diabetes
When the Q1 2027 results were published on November 12, 2026, management had indicated that the quarter confirmed its confidence in achieving its annual objectives. International markets are growing by nearly 20%, driven by Oxystore Italy and Intus in the United Kingdom, while the diabetes business is up more than 20%.
In terms of valuation, the share price stands 16.97% below its 200-day moving average (€22.98) and has fallen 16.86% over three months. The stock trades between support at €17.54 and resistance at €21, two levels that bound the current trading range. The analyst consensus remains available to help position the stock relative to its potential.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
SectorDispositifs médicaux et optique›Dispositifs médicaux
Context
Period
Period: T1 2027
Key reported figures
Revenue: 124,3 millions d'euros
Quarterly revenue: 124,3 millions d'euros
Revenue growth: 7,5 %
Guidance from the release
The Group's Q1 performance confirms the strength of its business momentum and its full confidence in achieving its full-year targets
Opportunities identified
International markets showing very strong momentum with growth of nearly 20%, driven by Oxystore Italy and Intus UK performances
Diabetes business recorded growth of more than 20% with positive volume and pricing effects
Respiratory care maintained strong momentum at 10.6% growth supported by structural market growth and market share gains
Outlook / guidance
Expected revenue: 500 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.